Press Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Nov 6, 2019-- Updated Results from the Pomalyst® and Kyprolis® Arms of the Phase 1b/2 STOMP Study Evaluating Selinexor in Combination with Other Approved Myeloma Therapies in Relapsed or Refractory Multiple Myeloma to be Highlighted --
NEWTON, Mass., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an oncology-focused pharmaceutical company, today announced that thirteen abstracts have been selected...
-
Nov 4, 2019− XPOVIO Phase 2b STORM Study Results Published in The New England Journal of Medicine −
NEWTON, Mass., Nov. 04, 2019 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an oncology-focused pharmaceutical company, today reported financial results for the third quarter...
-
Nov 1, 2019
NEWTON, Mass., Nov. 01, 2019 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), an oncology-focused pharmaceutical company, today announced that the Compensation Committee of...
-
Oct 28, 2019-- Conference Call Scheduled for Monday, November 4, 2019 at 8:30 a.m. ET --
NEWTON, Mass., Oct. 28, 2019 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an oncology-focused pharmaceutical company, today announced that it will report third quarter 2019...
-
Oct 1, 2019
NEWTON, Mass., Oct. 01, 2019 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a clinical-stage pharmaceutical company, today announced that the Compensation Committee of...